Erik Briers

Antwerpen, VLG, Belgium

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 59 publications

EORTC 2238 DE-ESCALATE: Revisiting Intermittent Maximal Androgen Blockade in Metastatic Hormone-sensitive Prostate Cancer.

EORTC 2238 DE-ESCALATE: Revisiting Intermittent Maximal Androgen Blockade in Metastatic Hormone-sensitive Prostate Cancer.

Journal: European urology

Published: June 08, 2026

Early and late CTCAE and patient-reported outcomes following lung cancer radiotherapy: A sex-stratified descriptive analysis from the REQUITE cohort.

Early and late CTCAE and patient-reported outcomes following lung cancer radiotherapy: A sex-stratified descriptive analysis from the REQUITE cohort.

Journal: Clinical and translational radiation oncology

Published: April 19, 2026

Early and late CTCAE and patient-reported outcomes following prostate radiotherapy in the REQUITE cohort.

Early and late CTCAE and patient-reported outcomes following prostate radiotherapy in the REQUITE cohort.

Journal: Clinical and translational radiation oncology

Published: April 17, 2026

EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II-2026 Update: Treatment of Relapsing and Metastatic Prostate Cancer.

EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II-2026 Update: Treatment of Relapsing and Metastatic Prostate Cancer.

Journal: European urology

Published: March 05, 2026

Balancing Cure and Quality of Life: Navigating Functional Outcomes in Localized Prostate Cancer.

Balancing Cure and Quality of Life: Navigating Functional Outcomes in Localized Prostate Cancer.

Journal: American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting

Published: March 05, 2026

EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2026 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent.

EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2026 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent.

Journal: European urology

Published: March 05, 2026

A plain language summary of the EORTC 1333/PEACE-3 study of enzalutamide alone vs enzalutamide plus radium-223 in patients with metastatic castrationresistant prostate cancer (mCRPC) and bone metastases.

A plain language summary of the EORTC 1333/PEACE-3 study of enzalutamide alone vs enzalutamide plus radium-223 in patients with metastatic castrationresistant prostate cancer (mCRPC) and bone metastases.

Journal: Future oncology (London, England)

Published: November 28, 2025

Beyond Menopause: Ending the Inequality-Why Men with Prostate Cancer Still Lack Therapies for Hot Flushes.

Beyond Menopause: Ending the Inequality-Why Men with Prostate Cancer Still Lack Therapies for Hot Flushes.

Journal: European urology

Published: November 12, 2025

Shared Decision-making in Urology: The SHINE-URO Consensus Framework.

Shared Decision-making in Urology: The SHINE-URO Consensus Framework.

Journal: European urology focus

Published: October 30, 2025

SPARC: The Importance for Patients with Prostate Cancer.

SPARC: The Importance for Patients with Prostate Cancer.

Journal: European urology

Published: September 22, 2025

Genetic determinants of fatigue up to 2 years after radiotherapy in prostate cancer patients.

Genetic determinants of fatigue up to 2 years after radiotherapy in prostate cancer patients.

Journal: Nature communications

Published: April 30, 2025

Professional-patient discrepancies in assessing lung cancer radiotherapy symptoms: An international multicentre study.

Professional-patient discrepancies in assessing lung cancer radiotherapy symptoms: An international multicentre study.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: October 23, 2024

Showing 1-12 of 59

Last Updated: 09/26/2026